Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

• Status: Completed
• Trial end date: 2020-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide. The study extension will evaluate the effect of one-dose of zoledronic acid after the teriparatide/denosumab combination.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Massachusetts General Hospital
• Treatments: Denosumab; Teriparatide; Zoledronic Acid

Criteria

Inclusion Criteria:

• women aged 45+

• postmenopausal

• osteoporotic with high risk of fracture

Exclusion Criteria:

• no significant previous use of bone health modifying treatments